The Cooper Companies (COO)
(Delayed Data from NSDQ)
$90.41 USD
+0.55 (0.61%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $90.41 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$90.41 USD
+0.55 (0.61%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $90.41 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum B VGM
Zacks News
The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.
LH vs. COO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LH vs. COO: Which Stock Is the Better Value Option?
Reasons to Hold The Cooper Companies (COO) in Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
LH or COO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LH vs. COO: Which Stock Is the Better Value Option?
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Reasons to Add The Cooper Companies (COO) to Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Company News for Mar 4, 2024
by Zacks Equity Research
Companies In The News Are: NTAP, MTZ, COO, TDW.
Cooper Companies (COO) Q1 Earnings Top, '24 Outlook Raised
by Zacks Equity Research
Cooper Companies' (COO) first-quarter fiscal 2024 revenues reflect a solid segmental performance with improved adjusted earnings amid rising expenses.
The Cooper Companies (COO) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for The Cooper Companies (COO) give insight into how the company performed in the quarter ended January 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
The Cooper Companies (COO) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of 7.59% and 1.80%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?
Patterson Cos. (PDCO) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Patterson Cos. (PDCO) delivered earnings and revenue surprises of -1.67% and 1.02%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Cooper Companies (COO) in Q1 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal first-quarter results are likely to reflect segmental strength.
Henry Schein (HSIC) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of -5.71% and 1.83%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Unveiling The Cooper Companies (COO) Q1 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of The Cooper Companies (COO) for the quarter ended January 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
The Cooper Companies (COO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
The Cooper Companies (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LH vs. COO: Which Stock Is the Better Value Option?
by Zacks Equity Research
LH vs. COO: Which Stock Is the Better Value Option?
Labcorp (LH) Surpasses Q4 Earnings and Revenue Estimates (Revised)
by Zacks Equity Research
Labcorp (LH) delivered earnings and revenue surprises of 0.30% and 0.86%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Labcorp (LH) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Labcorp (LH) delivered earnings and revenue surprises of 0.30% and 0.86%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Cooper Companies (COO), Fulgent Unite to Boost Genetic Testing
by Zacks Equity Research
Cooper Companies (COO) collaborates with Fulgent Genetics to boost newborn genetic screenings. CBR by Cooper Surgical is likely to provide a variety of genetic testing options to its families.
Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Cooper Companies (COO) Q4 Earnings In Line, '23 Outlook Raised
by Zacks Equity Research
Cooper Companies' (COO) fourth-quarter fiscal 2023 revenues reflect a solid segmental performance with improved adjusted earnings amid moderating expenses.
Compared to Estimates, The Cooper Companies (COO) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for The Cooper Companies (COO) give a sense of how its business performed in the quarter ended October 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
What's in Store for Cooper Companies (COO) in Q4 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.
The Cooper Companies (COO) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for The Cooper Companies (COO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended October 2023.
The Cooper Companies (COO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
The Cooper Companies (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reasons to Retain The Cooper Companies (COO) in Your Portfolio
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.